The University of Liège receives funding from the Interreg V-A programme (Greater Region) for the development of new bioMaterials for PROliferation and in vitro Expansion of STEM cells (Improve-Stem)

The University of Liège receives funding from the Interreg V-A programme (Greater Region) for the development of new bioMaterials for PROliferation and in vitro Expansion of STEM cells (Improve-Stem)

The Laboratory of Chemical Engineering (Pr. D. TOYE) and the Interfaculty Center for Biomaterials (C. GRANDFILS) from the University of Liège together with the University of Kaiserslautern, the Luxembourg Institute of Science and Technology (LIST), the Leibniz Institute for New Materials (INM), the University of Lorraine and the National Center for Scientific Research (CNRS) bring up keys competencies in materials sciences, bioprocess engineering and cell biology.

At the level of the Greater Region, this multidisciplinary consortium provides a solid basis for a platform of excellence in the field of mesenchymal stem cells culture.

Human Mesenchymal Stem Cells are multipotent cells, self-renewable, easily accessible and culturally expandable in vitro with exceptional genomic stability and few ethical issues, marking its importance in cell therapy, regenerative medicine and tissue repairmen (1). However, one of the main limiting steps in their clinical use is the amplification step.

MSC expansion on microcarriers has emerged during the last few years, fulfilling the lack of classical T-flasks expansion.

The aim of the project Improve-Stem is to develop new microcarriers with optimized surface design allowing the control of cell adhesion alongside to the design of an adapted bioreactor with operating conditions adjusted for stem cell culture on microcarriers.

About INTERREG V-A programme

The INTERREG V-A programme in the Greater Region aims at intensifying cross-border cooperation. This goal is to be achieved by means of local and regional projects between partners from the various areas in the Greater Region.

This programme is cofounded by European Union (Fonds Européen de Développement Régional)

1.Horwitz E.M., Le Blanc K., Dominici M., Mueller I., Slaper-Cortenbach I., Marini F.C., Deans R.J., Krause D.S., Keating A. International Society for Cellular Therapy. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy. 2005;7:393–395. doi: 10.1080/14653240500319234
Related articles

PDC*line Pharma is GMP accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for its Quality Control and Release Activities for PDC*lung, a drug for lung cancer immunotherapy

Liège (Belgium), 21st January 2019. PDC*line Pharma is delighted to announce, that the company is now accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for the Quality Control and Release activities of its anticancer agent PDC*lung, intended for the treatment of patients with lung cancer.  PDC*line Pharma is developing a new

Read more
PDC*line Pharma is GMP accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for its Quality Control and Release Activities for PDC*lung, a drug for lung cancer immunotherapy

First Congress in Health Simulation

The Medical Simulation Center of the University of Liège organizes its first congress in Health Simulation: “Towards evidence-based simulation”. Event will be held on Thursday, March 28th, 2019 in the faculty of medicine amphitheatres of Liège University, located on Sart-Tilman campus. Several themes will be discussed: Evidence-based Innovations and advances in simulation Medical education –

Read more
First Congress in Health Simulation

New University Certificate for clinical trials

The Clinical Sciences Department of the Medicine Faculty of the University of Liège organizes from the academic year 2018-2019 a University Certificate in clinical trials. More information is available in this folder

Read more
New University Certificate for clinical trials